Sign In
Buy SGMT
$6.86
+0.0700 (+1.03%)
At Close: Jun 03, 2026
Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference
08:00am, Wednesday, 22'nd Nov 2023
SAN MATEO, Calif., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors
Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
08:00am, Monday, 13'th Nov 2023
On track to report topline week 52 liver biopsy results from Phase 2b FASCINATE-2 trial with denifanstat in the first quarter of 2024
Combination treatment of a FASN inhibitor with semaglutide, a GLP-1 receptor agonist, improved several biomarkers associated with NASH in a mouse model and showed a significant improvement in liver fi
Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting® 2023
11:00am, Tuesday, 24'th Oct 2023
SAN MATEO, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic
Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference
04:05pm, Wednesday, 18'th Oct 2023
SAN MATEO, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that tar
Sagimet Biosciences: Recent IPO With Emerging Positive Data In NASH
02:48pm, Wednesday, 27'th Sep 2023
Sagimet Biosciences Inc. develops FASN inhibitors for diseases related to dysfunctional lipid metabolism. Their lead candidate, Denifanstat, shows promising results in treating nonalcoholic steatohepa
U.S. IPO Weekly Recap: July IPO Market Kicks Off With Sizable Biotechs
03:28am, Saturday, 15'th Jul 2023
Following the Independence Day lull, the July IPO market warmed up with two sizable biotechs, joined by two blank check companies. Surf Air Mobility delayed its direct listing until later this month.
